

Claims

1. Use of a myostatin antagonist in the manufacture of a medicament for use in accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery.
2. The use according to claim 1, wherein the myostatin antagonist is to be administered after confirmation of successful surgical hip repair and wound healing.
3. The use according to claim 1 or claim 2, wherein the myostatin antagonist is to be administered starting at about 7-42 days or about 1 to 6 weeks after surgery.
4. The use according to any one of claims 1 to 3, wherein the myostatin antagonist is to be administered in a patient starting when said patient is able to have weight-bearing walk with or without walking aid and initiate physical rehabilitation.
5. The use according to any one of claims 1-4, wherein the myostatin antagonist is a myostatin receptor binding molecule.
6. The use according to any one of claims 1-5, wherein the myostatin antagonist is an ActRII receptor antagonist.
7. The use according to any one of claims 1-6, wherein the myostatin antagonist is an anti-ActRII receptor antibody.
8. The use according to any one of claims 1-7, wherein the anti-ActRII receptor antibody is bimagrumab.
9. The use according to claim 8, wherein the myostatin antagonist is to be administered to a patient in need thereof at a dose of about 70-700 mg.
10. The use according to claim 8 or claim 9, wherein said myostatin antagonist is to be administered at a dose of about 70 mg, or about 210 mg or about 700 mg.
11. The use according to any one of claims 1-10, wherein said myostatin antagonist is to be administered intravenously.
12. The use according to any one of claims 1-11, wherein said myostatin antagonist is to

be administered every four weeks.

13. The use according to any one of claims 1-12, wherein said myostatin antagonist is to be administered for at least 3 months.

5

14. The use according to any one of claims 1-13, wherein said myostatin antagonist is to be administered for at about 6 months.

10

15. The use according to any one of claims 1-14, wherein said myostatin antagonist is to be administered for up to 12 months.

15

16. The use according to any one of claims 1-15, wherein said myostatin antagonist is to be administered to accelerate/improve physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery implying enhanced muscle growth, increased muscle strength and physical performance, improved self-perceived mobility, accelerated return to independence, and reduced risk of falls and injurious falls.

20

17. Bimagrumab for use in accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, wherein bimagrumab is to be administered intravenously at a dose of about 70-700 mg every four weeks.

25

18. Bimagrumab for use in accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, wherein bimagrumab is to be administered intravenously at a dose of about 70 mg every four weeks.

30

19. Bimagrumab for use in accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, wherein bimagrumab is to be administered intravenously at a dose of about 210 mg every four weeks.

35

20. Bimagrumab for use in accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, wherein bimagrumab is to be administered intravenously at a dose of about 700 mg every four weeks.

21. A composition comprising 150 mg/ml of bimagrumab for use in a method of accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery.
22. A unitary dosage form comprising 150 mg/ml of bimagrumab.
23. An infusion bag comprising an appropriate amount of bimagrumab from one or more vial(s) diluted with a solution.